Effective treatments are required for patients with diffuse large B‐cell lymphoma (DLBCL) with primary refractory disease. (June 2017) - Salas, Q.Q.; Domingo Domenech, E.; Mercadal, S.; Oliveira, A.; Aguilera, C.; De la Banda, E.; Climent, F.; Lucas, A.; Garcia, N.; Baca, C.; Fernandez de Sevilla, A.; Sureda, A.; et al.